
Atezolizumab Efficacy in Cervical Cancer Consistent Irrespective of PD-L1
A post hoc analysis of the pivotal phase 3 BEATcc trial (NCT03556839) has revealed that the clinical benefits of adding atezolizumab (Tecentriq) to standard chemotherapy and bevacizumab (Avastin) in patients with untreated recurrent or metastatic cervical …